Fangjun Luo's Contact Details

Fangjun Luo's Company Details

Novartis Institutes for BioMedical Research (NIBR)

Cambridge, Massachusetts, US • 3974 Employees
Major Drugs

Our people With more than 6,000 scientists, physicians and business professionals around the world, we have an open, entrepreneurial and innovative culture that encourages collaboration as we work to push the boundaries of science to change the practice of medicine. NIBR focuses on the following disease areas: • Autoimmunity, Transplantation, and Inflammatory Disease • Cardiovascular & Metabolic Diseases • Immuno-oncology • Infectious Diseases • Musculoskeletal Diseases • Neuroscience • Oncology • Ophthalmology • Respiratory Diseases NIBR has built expertise around several key technology competencies. Each competency combines automation and robotics, computational science, biology and irreplaceable drug discovery knowledge. By building expertise around key technologies, it can be more effectively applied across diseases that share similar mechanisms. • Analytical Sciences • Biologics • Biomarker Development • Chemistry • Developmental and Molecular Pathways • Drug Metabolism & Pharmacokinetics • Genomics Institute of the Novartis Research Foundation › Developing advanced technologies, ranging from cellular genomics and proteomics to combinatorial chemistry and structural biology • Imaging • Metabolism and Pharmacokinetics • Preclinical Safety • Proteomic Chemistry • Translational Medicine NIBR has locations in: • Basel, Switzerland • Cambridge, MA • East Hanover, NJ • Emeryville, CA (SF Bay Area) • San Diego, CA • Shanghai, China Thank you for taking an interest in the NIBR LinkedIn page. Please read Novartis' LinkedIn community guidelines: https://bit.ly/3yAl483